Airway Pressure Release Ventilation (APRV) vs conventional ventilation for patients with moderate to severe acute hypoxemic respiratory failure: the RELEASE trial

niversity of Warwick0 个研究点目标入组 710 人开始时间: 2024年6月21日最近更新: 2024年7月29日

适应症

试验速览

暂无简介。

•1. Age =18 years
•2. Receiving invasive mechanical ventilation
•3. Moderate to severe AHRF (PaO2/FiO2 <20 kPa with Positive End Expiratory Pressure (PEEP) =5 cmH2O) assessed at the time of screening (or as documented in the medical record in the preceding 2 hours)
•4. Expected to stay on invasive mechanical ventilation for >48 hours

•1. Receiving IMV =60 hours at the time of screening as will be unable to deliver early APRV
•2. Primary reason for invasive mechanical ventilation is one of the following:
•2.1. Asthma
•2.2. Severe COPD
•2.3. Pulmonary embolism (massive or sub-massive) (as cause of hypoxaemia is not primarily due to collapse of lung tissue)
•2.4. Existing neuromuscular disease such as motor neurone disease, Guillain Barre or myasthenia gravis (as the cause of respiratory failure is not primarily lung-related)
•3. Refractory shock (systolic blood pressure < 90 mmHg, despite fluid administration and vasoactive drugs)*
•4. Severe hypercapnic respiratory acidosis (pH <7.20 on the arterial blood gas assessed for trial inclusion)*
•5. Ongoing air leak (e.g. unresolved pneumothorax at time of screening)*
•6. Traumatic brain injury with uncontrolled intracranial hypertension*
•7. Likely death or treatment withdrawal in the next 24 hours
•8. Home ventilation or home oxygen therapy prior to admission
•*(patients can be recruited if this resolves and remain eligible)

发起方

niversity of Warwick